Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications

Pharmacol Res. 2020 Sep:159:104946. doi: 10.1016/j.phrs.2020.104946. Epub 2020 May 23.

Abstract

Coronavirus Disease 2019 (COVID-19) has sparked a global pandemic, affecting more than 4 million people worldwide. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause acute lung injury (ALI) and even acute respiratory distress syndrome (ARDS); with a fatality of 7.0 %. Accumulating evidence suggested that the progression of COVID-19 is associated with lymphopenia and excessive inflammation, and a subset of severe cases might exhibit cytokine storm triggered by secondary hemophagocytic lymphohistiocytosis (sHLH). Furthermore, secondary bacterial infection may contribute to the exacerbation of COVID-19. We recommend using both IL-10 and IL-6 as the indicators of cytokine storm, and monitoring the elevation of procalcitonin (PCT) as an alert for initiating antibacterial agents. Understanding the dynamic progression of SARS-CoV-2 infection is crucial to determine an effective treatment strategy to reduce the rising mortality of this global pandemic.

Keywords: Coronavirus; Cytokine storm; Immune escape; Inflammation; SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • Betacoronavirus*
  • Biomarkers / blood
  • COVID-19
  • Coronavirus Infections / blood*
  • Coronavirus Infections / etiology
  • Coronavirus Infections / immunology
  • Cytokines / blood
  • Disease Progression
  • Humans
  • Interleukin-10 / blood
  • Interleukin-6 / blood
  • Lymphopenia / etiology
  • Lymphopenia / immunology
  • Pandemics*
  • Pneumonia, Viral / blood*
  • Pneumonia, Viral / etiology
  • Pneumonia, Viral / immunology
  • Procalcitonin / blood
  • SARS-CoV-2

Substances

  • Biomarkers
  • Cytokines
  • IL10 protein, human
  • IL6 protein, human
  • Interleukin-6
  • Procalcitonin
  • Interleukin-10